Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
26 oct. 2021 08h27 HE
|
Purple Biotech Ltd.
Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies REHOVOT, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
22 oct. 2021 06h00 HE
|
Purple Biotech Ltd.
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy NT219, which Targets IRS, Shown to be Highly...
Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update
13 sept. 2021 07h00 HE
|
Purple Biotech Ltd.
One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab Patient Enrollment in Second Dose Cohort Complete Study Expanding...
Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
05 août 2021 08h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
04 juin 2021 08h00 HE
|
Purple Biotech Ltd.
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
26 mai 2021 07h38 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
20 mai 2021 07h00 HE
|
Purple Biotech Ltd.
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- ...
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
19 mai 2021 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
23 avr. 2021 08h00 HE
|
Purple Biotech Ltd.
Preliminary Data from First Part of Study Anticipated in Second Half of 2021 REHOVOT, Israel, April 23, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (Nasdaq/TASE: PPBT), a clinical-stage company...
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
13 avr. 2021 08h17 HE
|
Purple Biotech Ltd.
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...